Medtronic, Inc. Looks To Overturn $393 Million Heart Valve Loss To Edwards Lifesciences Corporation

Medtronic asks a Delaware federal judge to overturn a $393 million patent infringement loss to Edwards Lifesciences over their respective replacement heart valves. Medtronic (NYSE:MDT) asked a federal judge in Delaware this week to reverse a $393 million loss to Edwards Lifesciences (NYSE:EW) in their long-running patent infringement war over replacement heart valve technology. Last month a jury tagged Medtronic with the $393 million verdict, deciding that Medtronic's CoreValve device infringes a patent covering Edwards' Sapien device

Help employers find you! Check out all the jobs and post your resume.